 Andreas Hollenstein
Senior Principal Scientist
Roche
Switzerland |
Title:
Unmasking Hidden Epitopes: Bridging In Silico Prediction and MAPPs Detection in Immunogenicity Assessment
Abstract:
MHC-associated peptide proteomics (MAPPs) identifies presented peptides for immunogenicity assessment, though in silico tools often over-predict compared to experimental results. This study demonstrates that antibody modifications can reveal previously “missed” peptides, aligning MAPPs data with predictions. These results suggest that in silico hits are likely valid findings not discovered partly due to limited standard detection sensitivity.
Biography:
Andreas holds an MS in Biochemistry/Molecular Biology and completed his PhD at ETH Zürich in the field of Radio-Oncology. After postdoctoral research in adoptive cell therapy at the Dutch Cancer Institute in the lab of Ton Schumacher, he focused on antibody discovery and lead optimization at Genmab NL. Andreas joined Roche in Basel in 2020 as a scientist in immunosafety, where he focuses on the development of safer and less immunogenic therapeutics.
|
